CommercialCoverageLow impact
08.00.72l, Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ), Cipaglucosidase alfa-atga (Pombiliti™ )
Independence Blue Cross·Endocrinology, Neurology, Pediatrics·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
This is a reissued policy update for enzyme replacement therapy drugs used to treat Pompe disease, including Lumizyme®, Nexviazyme®, and Pombiliti™. The policy has been reissued with an effective date of April 1, 2026, suggesting updated coverage or administration requirements for these specialized medications.
Action Required
By April 1, 2026: Review updated policy requirements for alglucosidase alfa medications (Lumizyme®, Nexviazyme®, Pombiliti™) at the provided URL. Billing team should verify any changes to prior authorization, documentation, or coverage criteria for these Pompe disease treatments and update billing procedures accordingly.